MIRA PHARMACEUTICALS, INC.
Ketamir-2
chemotherapy-induced peripheral neuropathy
Date
TBD
Phase 1 readout · Date TBD estimated
What's at stake
Phase 1 trial results for Ketamir-2 in chemotherapy-induced peripheral neuropathy are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 13h ago
“The Company also stated that it plans to present Phase 1 data at an upcoming scientific meeting.”